Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
List view / Grid view
Filter the results
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
A team have shown that a tumour-suppressing and killing molecule delivered to the brain by stem cells has been successful in mice.
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.
Paradigm Shift in Drug Discovery: Discover Small Molecule Degraders Using E3scan™ Technology Platform
4 March 2021 | By Eurofins Discovery
Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.
As laboratories face the challenge of screening many samples for SARS-CoV-2, lab managers have turned to the use of automation to address key concerns.
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
A team of researchers have used microscopy techniques to monitor DNA degradation and anticancer drug release from nanostructures.
Researchers have shown that administering a urinary tract infection vaccine directly to the bladders of mice helped them to effectively fight bacteria.
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
26 February 2021 | By Domain Therapeutics
Register for our webinar which will focus on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.